BioMarin Pharmaceutical Analyst Price Targets

Wall Street analyst price targets and consensus rating for BioMarin Pharmaceutical (BMRN).

Price Target Range — 10 Quarters

Analyst Consensus — 28 Analysts

20Buy

8Hold

Consensus RatingBuy# Analysts28Avg. Consensus PT$89Upside to Avg. PT+62.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 21, 2026	Morgan Stanley	Matthew Harrison	PT Cut	Overweight	$124→$122
Oct 20, 2026	JP Morgan	Jessica Fye	PT Raise	Overweight	$86→$87
Oct 20, 2026	Cantor Fitzgerald	Olivia Brayer Saunders	Maintained	Overweight	$86
Oct 15, 2026	UBS	Joon Lee	Assumes	Buy	$114→$88
Oct 14, 2026	Barclays	Eliana Merle	PT Raise	Overweight	$111→$114
Sep 10, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Neutral	$60
Sep 1, 2026	Piper Sandler	Allison Bratzel	PT Raise	Overweight	$88→$90
Aug 31, 2026	Jefferies	Akash Tewari	PT Raise	Buy	$104→$105
Aug 31, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Neutral	$59→$60
Aug 19, 2026	BMO Capital	David Lebowitz	Initiate	Outperform	$98
Aug 18, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Neutral	$60→$59
Aug 17, 2026	Piper Sandler	Allison Bratzel	PT Raise	Overweight	$82→$88
Aug 17, 2026	Barclays	Eliana Merle	PT Raise	Overweight	$105→$111
Aug 10, 2026	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$111→$114
Aug 7, 2026	Morgan Stanley	Matthew Harrison	PT Raise	Overweight	$119→$124
Aug 7, 2026	Oppenheimer	Leland Gershell	PT Raise	Outperform	$95→$97
Aug 7, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Neutral	$50→$60
Jul 16, 2026	Citigroup	Eric Joseph	PT Raise	Buy	$75→$76
Jul 7, 2026	RBC Capital	Luca Issi	PT Cut	Sector Perform	$66→$62
May 22, 2026	Canaccord Genuity	Whitney Ijem	PT Cut	Buy	$116→$111

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $122

Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $124 to $122.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on BioMarin Pharmaceutical, Maintains $86 Price Target

Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and maintains $86 price target.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $114

Barclays analyst Eliana Merle maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $111 to $114.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and maintains $60 price target.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $90

Piper Sandler analyst Allison Bratzel maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $88 to $90.

Benzinga Newsdesk

PRO
Jefferies Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $105

Jefferies analyst Akash Tewari maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price target from $104 to $105.

Benzinga Newsdesk

BioMarin Pharmaceutical Inc

뉴스

파트너 / 기고자

벤징가 글로벌

BioMarin Pharmaceutical Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $122

PRO
Cantor Fitzgerald Reiterates Overweight on BioMarin Pharmaceutical, Maintains $86 Price Target

PRO
Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $114

PRO
HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target

PRO
Piper Sandler Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $90

PRO
Jefferies Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $105

People Also Watch

People Also Watch

BioMarin Pharmaceutical Inc

뉴스

파트너 / 기고자

벤징가 글로벌

BioMarin Pharmaceutical Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMorgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $122

PROCantor Fitzgerald Reiterates Overweight on BioMarin Pharmaceutical, Maintains $86 Price Target

PROBarclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $114

PROHC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target

PROPiper Sandler Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $90

PROJefferies Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $105

People Also Watch

People Also Watch

PRO
Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $122

PRO
Cantor Fitzgerald Reiterates Overweight on BioMarin Pharmaceutical, Maintains $86 Price Target

PRO
Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $114

PRO
HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target

PRO
Piper Sandler Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $90

PRO
Jefferies Maintains Buy on BioMarin Pharmaceutical, Raises Price Target to $105